The expression of HER2-low has been shown to be highly dynamic over time, with a significant portion of HER2-low tumors transitioning to HER2-0 and vice versa, either in residual disease following neoadjuvant therapy [13] or after tumor relapse [13,14]. The gene discussed is ERBB2; the disease is neoplasm.